Loading
A phase 2 trial of Dronabinol in Breast cancer, run by City of Hope Medical Center, now recruiting.
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors is a phase 2 interventional study registered as NCT06731894 by City of Hope Medical Center, with 120 participants planned, started 2025-10-03 and due to reach its primary completion in 2028-01-07. Interventions recorded: Biospecimen Collection, Cannabidiol, Dronabinol, Placebo Administration, Survey Administration. Conditions recorded: Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma.
Linked to the drug Dronabinol because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/